X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the agreement, Compugen provided an exclusive license to AstraZeneca to use its monospecific antibodies that bind to TIGIT, including AZD2936 (rilvegostomig), a PD-1/TIGIT bispecific antibody.
Lead Product(s): Rilvegostomig,Capecitabine
Therapeutic Area: Oncology Product Name: AZD2936
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: AstraZeneca
Deal Size: $210.0 million Upfront Cash: $10.0 million
Deal Type: Licensing Agreement January 08, 2024
Details:
Compugen will exclusively license its potential first-in-class, pre-clinical antibody program against IL-18 binding protein, including the COM503, a potential first-in-class, high affinity antibody which blocks the interaction between IL-18 binding protein and IL-18.
Lead Product(s): COM503
Therapeutic Area: Oncology Product Name: COM503
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Gilead Sciences
Deal Size: $848.0 million Upfront Cash: $60.0 million
Deal Type: Licensing Agreement December 19, 2023
Details:
Under the agreement, AstraZeneca has the rights for the development of bi-specific and multi-specific antibody products, including rilvegostomig, a PD-1/TIGIT bispecific antibody where the TIGIT component is derived from Compugen's clinical-stage anti-TIGIT antibody, COM902.
Lead Product(s): Rilvegostomig,Capecitabine
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: AstraZeneca
Deal Size: $210.0 million Upfront Cash: $10.0 million
Deal Type: Licensing Agreement December 19, 2023
Details:
COM701, a potential first-in-class anti-PVRIG antibody, is being developed in combination with COM902, Compugen's potential best-in-class anti-TIGIT antibody and pembrolizumab in patients with platinum resistant ovarian cancer.
Lead Product(s): COM701,COM902,Pembrolizumab
Therapeutic Area: Oncology Product Name: COM701
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 22, 2023
Details:
COM701, is a potentially first-in-class immunotherapy targeting PVRIG, a novel immune checkpoint that is computationally discovered and validated as a monotherapy and in combination with PD-1 blockers.
Lead Product(s): COM701,COM902
Therapeutic Area: Oncology Product Name: COM701
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 06, 2023
Details:
COM701 (anti-PVRIG) in dual and triple combination with nivolumab ± BMS-986207 demonstrated preliminary anti-tumor activity and immune activation in platinum resistant ovarian cancer patients and was well tolerated.
Lead Product(s): COM701,Nivolumab,BMS-986207
Therapeutic Area: Oncology Product Name: COM701
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 06, 2022
Details:
The advancement of AZD2936 into Phase 2 by AstraZeneca, a global leader in the development of oncology therapeutics, builds the confidence in the therapeutic potential of Compugen's anti-TIGIT antibody, COM902.
Lead Product(s): AZD2936
Therapeutic Area: Oncology Product Name: AZD2936
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: AstraZeneca
Deal Size: $210.0 million Upfront Cash: $10.0 million
Deal Type: Licensing Agreement November 16, 2022
Details:
COM701 in combination with nivolumab demonstrated encouraging 12% ORR in 3L+ MSS-CRC patients with liver metastases, compared to 0% ORR historically for other immunotherapies in a U.S. patient population.
Lead Product(s): COM701,Nivolumab
Therapeutic Area: Oncology Product Name: COM701
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 07, 2022
Details:
Clinical data of COM701, as a monotherapy and in combination with PD-1 blockers, have demonstrated initial signs of antitumor activity, with encouraging disease control rate, durability of responses and safety and tolerability in patients.
Lead Product(s): COM701,Nivolumab
Therapeutic Area: Oncology Product Name: COM701
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Bristol Myers Squibb
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 06, 2022
Details:
COM701 is a humanized antibody that binds with high affinity to PVRIG, a novel immune checkpoint discovered computationally by Compugen, blocking the interaction with its ligand, PVRL2.
Lead Product(s): COM701,Nivolumab
Therapeutic Area: Oncology Product Name: COM701
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 24, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
